Colorcon to Further its Technical Capabilities with New Containment Suite at its Pennsylvania Headquarters
Colorcon’s new suite will provide clients with capabilities to develop prototype tablets or capsule dosage forms when API quantity is limited or the API potency requires a higher level of protection.
Colorcon announced on May 18, 2021 that it has added a new containment suite to its global headquarters in Harleysville, Pa. to further expand its technical capabilities.
According to a company press release, the new suite will provide clients with capabilities to develop prototype tablets or capsule dosage forms when API quantity is limited or the API potency requires a higher level of protection.
“Investing in this facility demonstrates Colorcon’s continued commitment to supporting pharmaceutical development in North America, reducing our customer’s time to market, and reflects our dedication to providing unparalleled products and services,” said Kurt Fegely, managing director, Colorcon Americas, in the press release. “We can now offer a complete cycle starting from the customer’s API, all the way to a finished coated dosage form within our facilities and provide prototypes ready for customer evaluation.”
“Many of our customers, especially in early development phase, work with very small quantities of active ingredients, which can have unknown safety profiles and can also be extremely costly and limited in availability,” added Charlie Cunningham, technical director, Colorcon, in the press release. “Our investment in the best equipment enables us to produce tablets and capsules with milligrams of active product in the safest of conditions.”
Source: Colorcon
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
